Background: Antipsychotic drugs for the treatment of schizophrenia provide effective treatment of psychotic symptoms but might lead to neuroendocrine abnormalities.
INTRODUCTION
The onset of schizophrenia at the beginning of or during the reproductive years suggests that the disorder might be associated with cerebral and physiologic changes that begin in adolescence. In a study performed by Van Cauter et al, 1 plasma levels of prolactin, growth hormone, corticotropin, and cortisol were measured at 15-minute intervals for 24 hours in 9 unmedicated schizophrenic male patients and in 9 age-matched normal male subjects. Various abnormalities were found in response to neuroendocrine challenges, such as the dexamethasone suppression test. In the schizophrenic patients, the authors observed an almost 3-fold sleep-related increase in prolactin concentrations associated with intensified frequency of nocturnal prolactin pulses. This increased stimulatory effect of sleep on prolactin secretion became evident immediately after sleep onset. In addition, the normal inhibition of cortisol secretion during early sleep was absent in the patients with schizophrenia.
A study by Gil-Ad et al 2 reported abnormal growth hormone response to luteinizing hormone-releasing hormone (LHRH) and to thyrotropin-releasing hormone in adolescents with schizophrenia but not in adults with that condition. The authors suggested that such responses were the result of the interaction of developmental changes with the disease processes or the lower gonadotropin and testosterone concentrations seen in antipsychotic-drug-free patients with schizophrenia.
It has been suggested that serum prolactin concentrations increase in drugnaive male and female patients with schizophrenia. 3 In a study by Garver, 4 slightly higher prolactin concentrations were observed in untreated patients with acute schizophrenia than in treated patients with chronic schizophrenia or healthy individuals. Stress has also been associated with transient increases in prolactin and cortisol concentrations. 5,6 Higher prolactin and cortisol concentrations, in turn, might be attributable to the stimulatory effect of serotoninergic pathways. 7 Schizophrenia is a chronic disorder that requires long-term treatment with antipsychotic drugs. 8 Dopaminergic receptors can be found in cerebral pathways, such as the nigrostriatal, tuberoinfundibular, mesolimbic, and mesocortic systems. 9 Blockade of dopamine receptors in the tuberoinfundibular system stimulates prolactin release in lactotroph cells. Prolactin secretion is under (the influence of) tonic dopaminergic inhibition, which, in turn, is self-regulated by negative feedback. Typical antipsychotic drugs such as haloperidol have been associated with dose-dependent increases in prolactin secretion, 1°,11 probably due to their primary effect on the pituitary gland, 12,13 which results in the suppression of sex hormones. 14,15
Twenty-nine stable patients meeting criteria for schizophrenia or schizoaffective disorder were included in an open-label study performed by Kirkpatrick et a116 that evaluated prolactin secretion before and after abrupt withdrawal of a neuroleptic drug. The findings suggested that basal prolactin concentrations were significantly lower on postwithdrawal days 3, 4, and 5 than on subsequent days. The authors hypothesized that this rebound effect is a result of the changes that chronic neuroleptic administration produces in the dopaminergic receptors of the tuberoinfundibular system. The study by Markianos et a117 assessed prolactin responses to IM haloperidol 5 mg in the drug-free state and after 1 month of treatment with neuroleptics in 14 adult schizophrenic male patients who had never had drug treatment and in 20 adult schizophrenic male patients who had discontinued neuroleptic treatment for 2 months to 1 year. The results indicated that after discontinuation of neuroleptic drugs, the hypothalamic-pituitary dopamine receptors may remain sensitive for a long time.
Limited studies investigating hormone concentrations in patients with schizophrenia have produced inconsistent results. 18-2° Patients with schizophrenia might display a variety of hormone profiles.
Changes in hormone concentrations can affect mood, cognition, and behavior and can be the reason for sexual dysfunction and other clinical symptoms. An understanding of these mechanisms is necessary to improve clinical outcomes.
The aim of this study was to assess hypothalamic-pituitary-gonadal (HPG) axis function by comparing serum hormone concentrations from newly admitted male patients who were receiving antipsychotic drug treatment for psychotic disorders with patients who were antipsychotic-drug-free for the preceding 6 months.
PATIENTS AND METHODS
This cross-sectional study was conducted in 2 acute care public psychiatric inpatient units in Brazil--the Pax Clinica Psiqui~trica (Goi~nia) and the Clinica Santa Monica (Salvador). The local ethics committees and the ethics committee of the Federal University of Silo Paulo approved the study. The study was performed in accordance to the Declaration of Helsinki. 21 All participating patients (or their legal guardians) provided informed written consent.
All consecutive male patients aged 18 to 55 years admitted during a 1-year period (December 1999 to December 2000) who received a diagnosis of schizophrenia or related disorders according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 22 and scored >24 on the Brief Psychiatric Rating Scale 23 were eligible for the trial. We did not include women in the study, because the concentrations of gonadal hormones would have been affected by menstrual cycle phases, pregnancy and childbearing, and menopause. The study comprised newly admitted patients that were treated or untreated. Treated patients were those receiving treatment with antipsychotic drugs; untreated patients were those who had not received any antipsychotic drug for the previous 6 months.
The participants' charts were reviewed to collect data regarding their disorder history. Patients were assessed on admission by attending physicians using the Positive and Negative Syndrome Scale (PANSS). 24 On the morning after admission, blood samples were collected to determine serum concentrations of follicle-stimulating hormone (FSH), luteinizing hormone (LH), sex hormonebinding globulin (SHBG), prolactin, free testosterone (FT), and total testosterone (TT). Biochemical analyses of all hormones, with the exception of FT, were performed using a Wallac-Delfia 1234/1296 fluorometer (Perkin-Elmer Life Sciences Inc., Boston, Massachusetts). FT was measured by radioisotopic analysis using a Packard-Cobra II auto-gamma counter (Perkin-Elmer Life Sciences Inc.).
Gauss curves were used for displaying the distribution of the serum hormone concentrations of the treated and untreated patients compared with normal concentrations. These normal values were determined by analyzing blood samples taken from healthy controls and were provided by a commercial laboratory (Laborat6rio Fleury, Silo Paulo, Brazil). In addition to radioisotopic analysis, the normal FT concentration was also calculated using the serum concentrations of TT and SHBG. The normal serum concentrations of FSH, LH, and prolactin were determined using values obtained from samples sub-mitted to the laboratory by patients during a 30-day period; samples from patients enrolled in clinical studies, those receiving any drugs, and ill patients were excluded.
Statistical Analysis
The demographic and clinical data for the 2 patient groups were compared using the Fisher exact test. Descriptive statistics such as mean and standard deviation were used for describing the hormone data.
The nonparametric Mann-Whitney test was used for comparing the 2 independent groups of sampled data, making no assumptions about the distribution of the data. P values were obtained to compare hormone concentrations between the 2 patient groups. 25 The Kolmogorov-Smirnov test was used for testing the equality of distributions of hormone levels of the 2 patient groups compared with the control groups. 26 Statistical significance was set at P < 0.05 for the analysis.
RESULTS
Sixty-three male patients (mean [SD] age, 32.9 [9.5] years; range, 18-55 years) were included in the study. At admission, 76.2% (48) of the patients were receiving treatment with typical antipsychotic drugs (treated group); 15.9% (10) of these were concomitantly using an antidepressant. Fifteen (23.8%) patients had not received any antipsychotic or other psychotropic drug (untreated group) for _>6 months before admission. The mean (SD) PANSS score for positive symptoms for the entire study population was 23.3 (5.9), and the mean (SD) score for negative symptoms was 25.4 (5.8); the mean (SD) total PANSS score for the study population was 101.2 (23.1). The mean (SD) disease duration was 11.4 (9.0) years.
The only statistically significant differences in demographic characteristics between the 2 groups was the disease duration, which was significantly longer in the untreated group than in the treated group (12.3 [9.7] years vs 7.6 [8.1] years; P = 0.044) ( Table I) .
Control groups were derived from men in the same age range (18-55 years) as the study patients who were determined to be healthy and not receiving Table II shows the mean serum concentrations of prolactin, LH, FSH, TT, FT, and SHBG for the treated group, the untreated group, and the control groups. The treated group had significantly different serum concentrations of all hormones studied compared with the control groups (treated vs control: prolactin, 24.3 [23.7] No differences were found between the TT distribution curve of the controls and that of untreated patients (Figure 3) . The distribution curve of FT for the treated patients was shifted to the left, meaning that those patients had lower values than the controls (D = 0.6622; critical value of D = 0.2152).
Unfortunately, male-only prolactin curves were unavailable for the control group. However, patients in the treated and untreated groups had higher serum prolactin concentrations than the values obtained from the mixed-gender group of healthy controls.
DISCUSSION
Our results suggest that serum prolactin concentrations did not differ between untreated patients and treated patients. Several authors 27-3° have reported normal or decreased serum prolactin concentrations in drug-naive acute schizophrenic patients, as well as decreased prolactin concentrations in patients with chronic schizophrenia without ventricular dilatation. However, elevated serum prolactin concentrations have been reported after stress. 5,6,31 Therefore, given that our study population had acute psychotic symptoms at admission, the stress response might be responsible for the increased serum prolactin concen- 
Luteinizing hormone (LH) distribution curves for psychotic male patients receiving drug treatment (treated group), psychotic male patients not receiving drug treatment (untreated group), and healthy male controls (control group).
trations observed. On the other hand, in patients with a long history of illness who have undergone several previous treatments, the potential exists for the hypothalamic-pituitary dopamine receptors to remain sensitized for a long time after discontinuation of neuroleptic drugs. 17
Due to a lack of data (MEDLINE search; key terms: curve, normal distribution, hormone, drug-free, schizophrenia) on normal distributions of serum hormone concentrations in antipsychotic-drug-free patients with psychotic disorders, we compared the distribution curves of both treated and untreated patients with those of the control groups. We found that only the untreated patients had dispersion of hormone concentrations similar to that of the control groups. This supports the hypothesis made by Meltzer 32 that such drugs can alter hormone concentrations. However, these results might be misleading, because the curves of our matched controls might be different from those of a wider population of healthy individuals.
Serum concentrations of LH and FSH in treated patients suggested discrete shifts to values higher than those measured in the controls. This might be related to the slightly lower testosterone concentrations found in patients receiving antipsychotic treatment, because LH is responsible for the release of testosterone. When testosterone levels are low, the pituitary gland releases LH, leading to increased production of testosterone in the testicles. Follicle-stimulating hormone (FSH) distribution curves for psychotic male patients receiving drug treatment (treated group), psychotic male patients not receiving drug treatment (untreated group), and healthy male controls (control group).
Stress-related hormones influence reproductive function at 3 sites on the HPG axis: in the central nervous system, by inhibiting LHRH secretion; in the pituitary gland, by interfering with the LHRH-induced release of LH; and in the gonads, by altering the stimulating effect of gonadotropins on the secretion of sex steroids. 34 Humans exposed to acute stress respond with a small and often short-lived increase in plasma LH and testosterone concentrations. 35 The specific importance of endogenous testosterone is not fully understood, although it might be speculated that testosterone initiates recuperation. 36 Serum concentrations of FSH and TT in untreated patients were comparable to those of the controls, indicating that these hormones might normalize more rapidly than the other hormones after treatment is discontinued. This might also indicate that the other hormones are altered by the disease itself, or that FSH and TT concentrations changed in the untreated patients under stress, reaching more normal concentrations, while the treated patients reacted differently or in a less pronounced way to stress. The concentration of FT, which is the proportion of testosterone that is biologically active, was decreased in treated and untreated patients.
Analysis of the hormone distribution curves suggested that treated patients had greater dispersion than the healthy controls and the untreated patients. TT Concentration (nmol/L) Figure 3 . Total testosterone (TT) distribution curves for psychotic male patients receiving drug treatment (treated group), psychotic male patients not receiving drug treatment (untreated group), and healthy male controls (control group).
This might be explained by the fact that treated patients respond erratically to antipsychotic drugs, with great interindividual variation. Variations in response might also be the result of differences in regimen compliance. Findings regarding prolactin concentrations represent another important result of this study. We observed significantly higher serum prolactin concentrations in untreated patients than in the control groups. Therefore, our findings did not corroborate the view that a shift from prolactin-enhancing antipsychotic drugs to nonprolactin-enhancing atypical drugs is associated with normalizing prolactin concentrations. Based on our findings, patients who have undergone long-term treatment with antipsychotic drugs might experience a lower increase in prolactin concentrations over time, leading to lower levels overall. Another consideration is that in the acute period of a psychotic disorder, treated patients and untreated patients might have similar prolactin concentrations because cortisol interferes with the prolactin concentration. Thus prolactin concentrations in treated and untreated patients might reflect a nonspecific response to stress.
The clinical consequences of these findings need to be explored further. An interval of time would be required before adopting any drug treatment involv-ing the hormonal system, since the concentration of cortisol and other involved hormones are altered during this acute period of the disease.
There are some limitations to our analyses. Although statistically significant differences in serum hormone concentrations were not found between the 2 study groups, this might have been due to the small sample size (type 2 error). It is important to point out that our antipsychotic-drug-free patients were not drug-naive. Therefore, we were unable to determine whether there was a carryover effect associated with a drug that was not specific to psychotic symptoms. Because we measured hormone levels during acute episodes of psychotic disorders, the hormone changes might be associated with stress or to residual effects of the drug. In addition, the serum hormone concentration distribution curves of patients were compared with those of the controls. The serum hormone concentration distribution curves of drug-naive patients, which might be different, were not assessed in our analyses. Future studies would need to replicate these findings with a much larger sample size and would also benefit by inclusion of a matched control sample. Despite the methodologic limitations, we feel that the findings of this study are meaningful for understanding the hormonal physiology and pathophysiology of patients with schizophrenia, as well as its clinical consequences.
CONCLUSIONS
In this cross-sectional study of patients with acute psychotic disorders, we observed that serum prolactin concentrations were significantly higher in patients who were receiving antipsychotic drugs and in antipsychotic-drug-free patients than in healthy controls, although we found no difference between the 2 groups of patients. Despite the fact that concentrations of other hormones were within normal ranges in both treated and untreated patients, there was greater dispersion in the serum hormone concentration distribution curves of patients receiving antipsychotic drugs than those of untreated patients. This study supports further investigation of a potential difference in the HPG axis between patients with schizophrenia and those who do not have that condition.
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